SLC5A2 and hydrops fetalis: However, the relevance of ICDs in patients with NICM having an ejection fraction (EF) ≤35%, who are also receiving effective quadruple therapy (i.e., angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors) for HF has been a topic of debate. The purpose of this review is to analyze the benefits of preventive ICDs in NICM patients on adequate quadruple therapy for HF.